Second-line Therapy for Type 2 Diabetes

被引：0
|
作者：
Krome, Susanne
机构：
来源：
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2024年 / 149卷 / 19期
关键词：
D O I：
10.1055/a-2329-7522
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
About 9% of the world's population is affected by type 2 diabetes. The disease is usually progressive and is associated with multiple complications. If metformin fails to effectively lower HbA1c, additive sulfonylureas, SGLT-2 inhibitors and DPP-4 inhibitors are the most commonly used drugs. Randomized studies have mainly compared their benefits with placebo. Target trial emulation enabled direct comparison.
引用
收藏
页码：1127 / 1128
页数：2
相关论文
共 50 条
  • [41] Contemporary trends in the utilization of second-line Pharmacological therapies for type 2 diabetes in the United States
    Abrahami, Devin
    D'Andrea, Elvira
    Kim, Seoyoung
    Paik, Julie
    Wexler, Deborah
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 28 - 28
  • [42] Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia
    Bekele, Mengistu
    Norheim, Ole Frithjof
    Hailu, Alemayehu
    MDM POLICY & PRACTICE, 2021, 6 (01)
  • [43] Durability of Second-Line Oral Glucose-Lowering Therapy in Type 2 Diabetes: Results of a Large UK Cohort Study
    Mamza, Jil
    Mehta, Raj
    Donnelly, Richard
    Idris, Iskandar
    DIABETES, 2015, 64 : A39 - A39
  • [44] Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin
    Kristen DeCarlo
    Amisha Wallia
    Raymond H. Kang
    Andrew Cooper
    Manisha Cherupally
    Sterling A. Harris
    Cassandra Aikman
    David T. Liss
    Ronald T. Ackermann
    Matthew J. O’Brien
    BMC Geriatrics, 22
  • [45] Quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: the global DISCOVER study
    Nicolucci, A.
    Gomes, M. B.
    Khunti, K.
    Kosiborod, M.
    Pocock, S.
    Rathmann, W.
    Shestakova, M. V.
    Shimomura, I.
    Watada, H.
    Chen, H.
    Cid-Ruzafa, J.
    Fenici, P.
    Hammar, N.
    Tang, F.
    Ji, L.
    DIABETOLOGIA, 2018, 61 : S173 - S174
  • [46] Change in glycated haemoglobin levels after initiating second-line therapy in type 2 diabetes: a primary care database study
    Rathmann, W.
    Bongaerts, B.
    Kostev, K.
    DIABETES OBESITY & METABOLISM, 2016, 18 (08): : 840 - 843
  • [47] Trends in Timing of and Glycemia at Initiation of Second-line Type 2 Diabetes Treatment in US Adults
    Raghavan, Sridharan
    Warsavage, Theodore
    Liu, Wenhui G.
    Raffle, Katherine
    Josey, Kevin
    Saxon, David R.
    Phillips, Lawrence S.
    Caplan, Liron
    Reusch, Jane E. B.
    DIABETES CARE, 2022, 45 (06) : 1335 - 1345
  • [48] Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme
    Khunti, Kamlesh
    Chen, Hungta
    Cid-Ruzafa, Javier
    Fenici, Peter
    Gomes, Marilia B.
    Hammar, Niklas
    Ji, Linong
    Kosiborod, Mikhail
    Pocock, Stuart
    Shestakova, Marina, V
    Shimomura, Iichiro
    Tang, Fengming
    Watada, Hirotaka
    Nicolucci, Antonio
    DIABETES OBESITY & METABOLISM, 2020, 22 (01): : 66 - 78
  • [49] Global prevalence of type 2 diabetes complications in 14,391 patients initiating second-line therapy: the DISCOVER study
    Shestakova, M. V.
    Khunti, K.
    Arya, N.
    Cid-Ruzafa, J.
    Fenici, P.
    Gomes, M. B.
    Hammar, N.
    Nicolucci, A.
    Pocock, S.
    Rathmann, W.
    Watada, H.
    Shimomura, I.
    Tang, F.
    Kosiborod, M.
    DIABETOLOGIA, 2017, 60 : S518 - S519
  • [50] Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin
    DeCarlo, Kristen
    Wallia, Amisha
    Kang, Raymond H.
    Cooper, Andrew
    Cherupally, Manisha
    Harris, Sterling A.
    Aikman, Cassandra
    Liss, David T.
    Ackermann, Ronald T.
    O'Brien, Matthew J.
    BMC GERIATRICS, 2022, 22 (01)
12345